DIIT Press Release

University of Minnesota begins clinical trials for type 1 diabetes.
MINNEAPOLIS / ST. PAUL (May 8, 2008)—Researchers at the University of Minnesota’s Diabetes Institute for Immunology and Transplantation announce the start of new clinical trials for people with type 1 diabetes. The University is one of only seven sites in the United States funded by the National Institutes of Health as part of the Clinical Islet Transplantation Consortium, the goal of which is to determine whether islet transplantation becomes an FDA-approved treatment for people with difficult-to-manage type 1 diabetes.

“The University of Minnesota has long been a leader in islet transplantation for type 1 diabetes,” said Dr. Bernhard Hering, primary investigator for the University of Minnesota studies. “As we recruit individuals suffering from type 1 diabetes to take part in these crucial trials, we have the opportunity to help determine whether this experimental treatment becomes more widely available.”

To read the entire press release, visit the University of Minnesota Department of Surgery's web pages.

BETA CELL REPLACEMENT

For information on type 1 diabetes studies and assessing risk of type 1 diabetes in relatives of those with type 1 diabetes, please visit the Type 1 Diabetes TrialNet web site at www.diabetesstudies.umn.edu.